Ranbaxy extends losses in Q3 but merger with Sun on track
This article was originally published in Scrip
Executive Summary
Ahead of its proposed combination with Sun Pharma, Ranbaxy Laboratories reported disappointing numbers for the third quarter ended December 2014, with net losses widening to INR10.29bn ($168m) dented by higher finance costs and foreign exchange losses.
You may also be interested in...
SARS-CoV-2 Variants And Current Vaccines: “It’s Not All Or Nothing”
Experts including renowned virologist Peter Piot, FDA’s Peter Marks and CEPI’s Richard Hatchett discussed multiple dimensions pertaining to coronavirus variants and existing vaccines at a recent conference, noting enhanced post-deployment surveillance is underway in the US. While there’s no need to panic for every variant that emerges, equitable access to vaccines is critical to ensure that gains made over last year are not undone, they said.
Merck & Co, Indian Firms On Tackling Supply Chain Risks And A Hijack
Merck & Co. executive outlines how the company could sustain a “compliant supply performance” amid the pandemic, while senior officials from Sun Pharma, Cipla, Zydus Cadila and Biocon shared insights on coping with supply chain turbulence and moving away from over-dependence on China for starting materials.
Novartis Says It Hired Over 1,600 Amid Job Cuts Speculation In India
Novartis counters speculation around pandemic-related staff cutbacks in India, saying that it actually upped the number of hires across its operations since January 2020. A senior executive separately provides a buoyant outlook for the Swiss firm’s global services operations in Hyderabad, which has added a significant number of new roles.
Need a specific report? 1000+ reports available
Buy Reports